Compare SBAC & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBAC | VTRS |
|---|---|---|
| Founded | 1989 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 17.2B |
| IPO Year | 1999 | 2019 |
| Metric | SBAC | VTRS |
|---|---|---|
| Price | $219.19 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $236.89 | $13.50 |
| AVG Volume (30 Days) | 1.6M | ★ 7.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 2.28% | ★ 3.25% |
| EPS Growth | ★ 41.21 | N/A |
| EPS | ★ 9.80 | N/A |
| Revenue | $2,815,139,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $2.80 | $4.41 |
| Revenue Next Year | $2.76 | $1.96 |
| P/E Ratio | $22.33 | ★ N/A |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $162.41 | $8.12 |
| 52 Week High | $245.13 | $16.47 |
| Indicator | SBAC | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 58.62 |
| Support Level | $215.08 | $12.90 |
| Resistance Level | $225.33 | $16.38 |
| Average True Range (ATR) | 7.10 | 0.38 |
| MACD | 0.21 | 0.14 |
| Stochastic Oscillator | 77.85 | 68.97 |
SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.